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Objective: We attempted to investigate the safety and efﬁcacy of alternative weekly topotecan dosing in a
heavily pretreated Taiwanese population with recurrent epithelial ovarian cancer (EOC) and primary
peritoneal carcinoma (PPC).
Materials and methods: We retrospectively reviewed the medical records of patients with recurrent EOC
and PPC who had been treated with weekly topotecan between November 2008 and May 2012. Top-
otecan was given at a dose of 2.75e4 mg/m2 via a 30-minute intravenous (IV) infusion on Days 1, 8, and
15 of a 28-day cycle until disease progression or unacceptable toxicity occurred.
Results: Thirty-two patients were identiﬁed and 24 (75%) of them had received at least two previous
regimens of chemotherapy; the median number of treatment courses was seven. The main toxicities
(Grades 3 and 4) were anemia in seven (21.9%), neutropenia in six (18.8%), and thrombocytopenia in two
patients (6.2%). No deaths were attributable to the therapy. Overall, seven patients (21.9%) showed a
partial response (PR), while seven patients (21.9%) with stable disease (SD) were observed. Furthermore,
we found a favorable response and toxicity proﬁle in patients who received the lowest dose intensity
(2.75 mg/m2). The median progression-free survival (PFS) and overall survival (OS) were 3 months [95%
conﬁdence interval (CI) 2.7e3.2] and 20 months (95% CI 11.1e28.9), respectively.
Conclusion: Topotecan administered as a weekly dosage (2.75e4 mg/m2) seems to be a tolerable regimen
with modest activity in a Taiwanese population. Although the lower dose schedule showed a higher
response with a better toxicity proﬁle, further studies with more cases are needed to conﬁrm this
ﬁnding.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Epithelial ovarian cancer (EOC) continues to be the leading
cause of death among women with gynecologic malignancies and
the 10th leading cause of cancer death in women in Taiwan [1].
Because no effective strategy exists for screening of ovarian cancer,
most of the patients were diagnosed with advanced-stage diseases.
Surgical cytoreduction combined with platinum and taxaneand Gynecology, Kaohsiung
ei Road, Niao Sung District,
4237@yahoo.com.tw (H. Lin).
bstetrics & Gynecology. Publishedchemotherapy is the currently preferred initial management for
women with Stage III or Stage IV EOC. Most patients, however, will
experience recurrence and only about 10e45% survive for 5 years
[2]. Primary peritoneal carcinoma (PPC) behaves in a manner
similar to that of EOC. For patients with platinum-sensitive tumors
upon relapse, platinum-doublet agents may be selected for salvage
treatment; however, for those with platinum-refractory or
platinum-resistant tumors, the nonplatinum single-agent treat-
ment options are recommended, including docetaxel, etoposide,
gemcitabine, pegylated liposomal doxorubicin, and topotecan [3].
Topotecan (Hycamtin; GlaxoSmithKline, Philadelphia, PA, USA),
a topoisomerase I inhibitor, is a valid and widely used second-line
therapeutic approach for recurrent EOC and PPC, both in patients
with platinum-sensitive and platinum-resistant disease. Theby Elsevier Taiwan LLC. All rights reserved.
C.-F. Hu et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 43e4744approved topotecan dosing by the Food and Drug Administration
(FDA) in 1996 and many other Western countries is a 1.5 mg/m2/
d intravenous (IV) infusion over 30 minutes on Days 1e5 of a 3-
week schedule. The response rates were reported to be 19e33%
for platinum-sensitive disease and 14e18% for platinum-resistant
disease. Although the regimen demonstrates signiﬁcant anti-
tumor activity, high morbidity associated with Grade 3/4 myelo-
suppression, fatigue, and neutropenic fever was observed [4].
Therefore, alternative topotecan dosing schedules are being eval-
uated in several studies. One such strategy has been the develop-
ment of weekly dosing schedules. Weekly administration of
topotecan at a dose of 4 mg/m2 has been uniformly conﬁrmed to be
less toxic but as effective as the 5-day regimen in multiple Phase II
studies [4]. However, racial disparity may exist in terms of treat-
ment response and toxicity. A previous study evaluated racial dis-
parities in treatment toxicity among patients with advanced EOC
and found that black women had signiﬁcantly less Grade 3/4
leukopenia and gastrointestinal toxicity than Caucasianwomen [5].
Therefore, there is an urgent need to evaluate whether this alter-
native dosing schedule is safe in a Taiwanese population. In this
study, we attempted to provide our experience of using weekly
topotecan for the treatment of heavily pretreated recurrent EOC
and PPC and to investigate the safety and efﬁcacy of this type of
alternative dosing.
Materials and methods
We retrospectively reviewed the medical records of patients
with recurrent EOC and PPC who had been treated with weekly
topotecan at the Department of Obstetrics and Gynecology, Kaoh-
siung Chang Gung Memorial Hospital, Taiwan, between November
2008 and May 2012. A total of 37 patients were identiﬁed initially;
however, ﬁve patients discontinued treatment for personal reasons
after receiving only one or two courses of weekly topotecan. These
patients were considered to be unsuitable candidates for efﬁcacy
and safety evaluation and were excluded. Finally, a total of 32 pa-
tients were eligible for this study. All of them had previously been
exposed to at least one regimen of platinum-based chemotherapy,
and had an acceptable performance status [Eastern Cooperative
Oncology Group (ECOG)  2]. Patients were categorized as having
platinum-sensitive disease (a relapse-free interval of longer than 6
months after primary therapy) or platinum-resistant disease
(relapse within 6 months). All the patients had elevated cancer
antigen-125 (CA-125) levels or clinically measurable disease as well
as adequate bone marrow, hepatic, and renal function before
treatment. Tumor response could be evaluated either serologically
using the change in CA-125 level or by radiologic signs of regression
or progression.
Topotecan was administered at a dosage ranging between
2.75 mg/m2 and 4 mg/m2 every week via a 30-minute IV infusion
on Days 1, 8, and 15 of a 28-day cycle until disease progression or
unacceptable toxicity occurred. The initial dose was chosen ac-
cording to the patient's performance status, general medical con-
dition, the number of previous chemotherapy regimens pretreated,
or physicians' preference. All patients had a CA-125 level evaluation
every 4 weeks, and an imaging study was arranged in some cases
for patients as indicated. All patients were assessed for toxicity
based on the National Cancer Institute Common Toxicity Criteria
(CTC) and tumor response according to Gynecologic Cancer Inter
Group (GCIG) criteria for change in serum CA-125 level [6]. Brieﬂy,
two pretreatment serum measurements at least twice ( 70 U/mL)
the upper limit of normal (ULN) (> 35 U/mL) and at least two
additional serum measurements after the start of treatment were
required to have assessable disease. A 50% reduction of the pre-
treatment serum CA-125 level that was sustained over 28 daysindicated a response. A complete response (CR) was deﬁned as a
reduction in CA-125 below the ULN that was sustained for at least
28 days. Otherwise, patients meeting the response criteria were
classiﬁed as having partial responses (PRs). Progression was
deﬁned as a two-fold increase in the ULN if the nadir value was less
than the ULN or a two-fold increase in the nadir value if the nadir
value was greater than the ULN or death. Response Criteria in Solid
Tumors (RECIST v1.1) was also applied in patients with measurable
disease [7]. Brieﬂy, a CR was deﬁned as complete disappearance of
all measurable disease; a PR was documented in patients with a
greater than 50% decrease in the size of measurable lesions; stable
disease (SD) was deﬁned as a reduction of less than 50% or an in-
crease of less than 25% in the tumor lesion; and progressive disease
(PD) was deﬁned as an increase of more than 25% in the tumor
lesion compared with the status before treatment. Progression-free
survival (PFS) was calculated as the period from the treatment
initiation to the time of documented progression. Overall survival
(OS) was measured as the period from the ﬁrst day of topotecan
treatment to death or the date of analysis. This study was approved
by the Institutional Review Board of Chang Gung Memorial
Hospital.
Statistical analysis
The signiﬁcance of the difference in percentage was calculated
using a c2/Fisher's exact test. PFS and OS analyses were calculated
by the KaplaneMeier method. A p value of less than 0.05 was
required for statistical signiﬁcance. Data processing and statistical
analysis was performed using the Statistical Package for Social
Sciences software package (version 17 for Windows; SPSS Inc.,
Chicago, IL, USA).
Results
All the 32 patients were eligible for treatment evaluation. The
characteristics of our patients are outlined in Table 1. The median
age was 58 years (range 29e83 years). Most patients had serous
histology (68.8%) and an ECOG performance status of 0 (65.6%). The
majority of patients (81.3%) had International Federation of Gyne-
cology and Obstetrics (FIGO) Stage III or Stage IV disease at initial
diagnosis. Most of the patients (75%) had received at least two
previous regimens of chemotherapy. Twenty (62.5%) had platinum-
sensitive disease while 12 (37.5%) had platinum-resistant disease.
For 29 patients (90.6%) with elevated CA-125 levels at the start of
weekly topotecan treatment, we used GCIG criteria for evaluation
of the treatment response. For the other three patients (9.4%) with
normal serum CA-125 levels, but obvious morphologic evidence of
disease recurrence (liver or lung metastasis conﬁrmed by
computed tomography or palpable neck metastatic lymph node),
we adopted RECIST for response determination. Overall, 318 cour-
ses of weekly topotecanwere administered, with a median number
of seven courses per patient (range 3e45 courses). A dose of 4 mg/
m2, 3.5 mg/m2, and 2.75 mg/m2 was given in 20, ﬁve, and seven
patients, respectively. There were no differences in patient char-
acteristics among the groups receiving different topotecan dose
intensities (Table 2).
Table 3 shows the treatment response in relation to different
clinical characteristics. The median PFS was 3 months [95% conﬁ-
dence interval (CI) 2.7e3.2]. Ten of the 32 patients (31.3%) are still
alive with disease at the time of analysis with a median OS of 20
months (95% CI 11.1e28.9) (Fig. 1A,B). The overall response rate
(ORR) was 21.9% (7 of 32 patients). No patients experienced a CR.
Seven patients (21.9%) had a PR, SD was observed in 7 patients
(21.9%), and PD occurred in 18 patients (56.2%). No deaths were
attributable to therapy. Of the 20 patients with platinum-sensitive
Table 3
Clinical response in relation to different clinical characteristics (N ¼ 32).
Characteristic p
Courses of chemotherapy, median (range) 7 (3e45)
Overall clinical response
Complete response (CR) 0 (0%)
Partial response (PR) 7 (21.9%)
Stable disease (SD) 7 (21.9%)
Progressive disease (PD) 18 (56.2%)
Platinum-sensitivity 0.292
Sensitive (n ¼ 20)
PR 4 (20.0%)
SD 6 (30.0%)
PR þ SD 10 (50.0%)
Resistant (n ¼ 12)
PR 3 (25.0%)
SD 1 (8.3%)
PR þ SD 4 (33.3%)
Topotecan dosage, mg/m2 0.001
4 (n ¼ 20) PR 2 (10%)
SD 3 (15%)
3.5 (n ¼ 5) PR 0 (0%)
SD 3 (60.0%)
2.75 (n ¼ 7) PR 5 (71.4%)
SD 1 (14.3%)
Previous chemotherapy regimens 0.386
1 (n ¼ 8) PR 2 (25.0%)
SD 3 (37.5%)
 2 (n ¼ 24) PR 5 (20.8%)
SD 4 (16.7%)
Table 1
Baseline clinical characteristics of patients.
Characteristic Number of patients (%)
Median age (y) 58 (range 29e83)
Epithelial ovarian cancer 30 (93.8)
Primary peritoneal cancer 2 (6.2)
Histologic type
Serous 22 (68.8)
Mucinous 1 (3.1)
Endometrioid 4 (12.5)
Clear cell 3 (9.4)
Undifferentiated carcinoma 2 (6.3)
ECOG performance status
0 21 (65.6)
1 7 (21.9)
2 4 (12.5)
FIGO stage
I 3 (9.4)
II 2 (6.3)
III 22 (68.8)
IV 4 (12.5)
Unstaged 1 (3.1)
Previous chemotherapy regimens
1 8 (25.0)
2 14 (43.8)
3 4 (12.5)
4 or more 6 (18.7)
Platinum sensitivity
Sensitive 20 (62.5)
Resistant 12 (37.5)
CA-125 level before therapy (U/mL)
 35 3 (9.4)
> 35 29 (90.6)
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had PD (50.0%). Of the 12 patients with platinum-resistant disease,
three patients had a PR (25.0%), one had SD (8.3%), and eight had PD
(66.6%). No signiﬁcant difference was observed between these two
groups of patients in terms of PR and clinical beneﬁt rate (PR þ SD).
The ORR for patients with different numbers of previous chemo-
therapy regimens was similar (25% and 20.8%). However, we found
a favorable ORR (71.4%) in patients who received the lowest dose
intensity (2.75 mg/m2), although no survival beneﬁt was observed
(Fig. 1C). Because of the similarity in patient characteristics, the
better response in the low-dose group was not related to more
favorable clinical characteristics such as low stage, more platinum-
sensitive disease, or fewer previous chemotherapy treatments.Table 2
Clinical characteristics of the three groups using different doses.
Characteristic Topotecan dosage (mg/m2)
4, n ¼ 20 (%) 3.5, n ¼ 5 (%) 2.75, n ¼ 7 (%)
ECOG performance status
0 13 (65) 3 (60) 5 (71)
1 4 (20) 2 (40) 1 (14)
2 3 (15) 0 (0) 1 (14)
FIGO stage
I 2 (10) 0 (0) 1 (14)
II 1 (5) 0 (0) 1 (14)
III 16 (80) 5 (100) 2 (29)
IV 1 (5) 0 (0) 3 (43)
Previous chemotherapy regimens
1 5 (25) 1 (20) 2 (29)
2 10 (50) 2 (40) 2 (29)
3 3 (15) 0 (0) 1 (14)
4 or more 2 (10) 2 (40) 2 (29)
Platinum sensitivity
Sensitive 12 (60) 4 (80) 4 (57)
Resistant 8 (40) 1 (20) 3 (43)Table 4 shows the major adverse effects in terms of dose in-
tensity and the number of previous chemotherapy treatment reg-
imens. Overall, Grade 3/4 neutropenia was observed in six patients
(18.8%). Grade 3/4 anemia and thrombocytopenia occurred in seven
(21.9%) and two (6.2%) patients, respectively. Two patients devel-
oped neutropenic fever, which was transient and manageable with
supportive care. Five patients received colony-stimulating factors
for bone marrow support, while seven patients received blood
transfusions for anemia. No patient withdrew from treatment due
to toxicity. The most common nonhematologic toxicities were fa-
tigue and nausea/vomiting. However, most nonhematologic toxic-
ities were mild with only one (3.1%) patient experienced Grade 3
vomiting. Our results also suggested a more favorable toxicity
proﬁle in patients who had received the lowest dose intensity
(2.75 mg/m2) and only one previous chemotherapy regimen.Discussion
This study appears to be the ﬁrst report investigating an Asian
population of recurrent EOC and PPC treated with weekly top-
otecan. We demonstrated a comparable toxicity proﬁle in a
Taiwanese population to that observed in other Western countries
using a topotecan dosage of 4 mg/m2/wk. Homesley et al [8] were
the ﬁrst to assess optimal weekly topotecan dosage. In that study,
the maximum tolerated and recommended dose was found to be
4mg/m2, and doses below 2mg/m2 lacked antitumor activity. Later,
several Phase II studies universally using 4 mg/m2/wk IV bolus
showed a similar response rate of 15e20% and Grade 3/4 neu-
tropenia in 15e20% of patients with recurrent EOC/PPC [9e15]. It is
interesting that our study also provided information that weekly
topotecan administration at the lowest dose intensity of 2.75 mg/
m2 exhibited a more favorable efﬁcacy. Moreover, no Grade 3/4
toxicity was found in this dosing group. However, due to the
paucity of large sample sizes, further study is needed to provide
strong evidence of more safety without compromising the thera-
peutic index of weekly topotecan in the lower dosing population. In
Fig. 1. (A) Progression-free survival (PFS). (B) Overall survival (OS). (C) There was no
signiﬁcant difference with regard to OS among those receiving different dose in-
tensities of weekly topotecan.
Table 4
Comparison of major toxicity (Grade 3/4) at different dose intensities and different
number of previous chemotherapy regimens.
Overall
toxicity
Topotecan dosage
(mg/m2)
Number of previous
chemotherapy
regimens
N ¼ 32
(%)
4 3.5 2.75 1  2
n ¼ 20
(%)
n ¼ 5
(%)
n ¼ 7
(%)
n ¼ 8
(%)
n ¼ 24
(%)
Hematologic
Leukopenia 4 (12.5) 2 (10) 2 (40) 0 (0) 0 (0) 4 (16.7)
Neutropenia 6 (18.8) 4 (20) 2 (40) 0 (0) 1 (12.5) 5 (20.8)
Anemia 7 (21.9) 7 (35) 0 (0) 0 (0) 1 (12.5) 6 (25.0)
Thrombocytopenia 2 (6.2) 1 (5) 1 (20) 0 (0) 0 (0) 2 (8.3)
Nonhematologic
Fatigue 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Nausea/vomiting 1 (3.1) 1 (5) 0 (0) 0 (0) 0 (0) 1 (4.1)
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was equivalent to the platinum-resistant group (23.1%), which was
quite different to that of previous results. Reasons for this may
include the fact that all the patients in the platinum-sensitive group
had received platinum-based chemotherapy retreatment at ﬁrst
relapse. Thus patients in the platinum-sensitive group were moreheavily pretreated than those in the platinum-resistant group in
our study. The greater the number of chemotherapy pretreatments,
the greater the chance that tumor cells would develop resistance
[16].
Although weekly topotecan can improve the toxicity proﬁle
without compromising antitumor activity in several Phase II trials,
studies directly comparing weekly and conventional protocols are
still limited. Largillier et al [17] were the ﬁrst to report their
experience of using two different types of dosing retrospectively.
They found a signiﬁcantly higher percentage of Grade 3/4 hema-
tologic toxicities in the conventional arm including neutropenia
(95.8% vs. 33.3%), anemia (37.5% vs. 9.5%), and thrombocytopenia
(33.3% vs. 4.8%). However, there were no signiﬁcant differences in
terms of treatment response and OS. Later, both the Gynecologic
Oncology Group (GOG) and the North Eastern German Society of
Gynecological Oncology (NOGGO) conducted prospective trials
comparing the conventional with theweekly schedule of topotecan
[18,19]. In contrast to the previous retrospective study, the results of
the two prospective trials showed less activity with weekly top-
otecan dosing. The response rates in the conventional versus
weekly regimens in GOG and NOGGO trials were 27% versus 12%
and 19% versus 9%, respectively. In the NOGGO trial, conventional
dosing improved PFS (marginal signiﬁcance) but not OS. In the GOG
trial, the accrual on the conventional armwas insufﬁcient and thus
the survival data could not be analyzed. However, both prospective
trials showed a hematologic toxicity proﬁle in favor of weekly
dosing. Therefore, both studies concluded that with regard to
effectiveness in terms of response and PFS, conventional dosing
remains the standard of care in patients with recurrent EOC.
However, comparable OS rates and a favorable toxicity proﬁle make
weekly dosing an acceptable alternative in this setting.
An added beneﬁt of the weekly IV bolus schedule is its greater
convenience when compared with the conventional 5-day
regimen. Also, weekly dosing may allow clinicians to monitor pa-
tients more frequently. Moreover, the improved hematologic
toxicity proﬁle of the weekly dosing may allow greater tolerability
in combining topotecan with other antitumor agents such as
gemcitabine [20], docetaxel [21], paclitaxel [22], or carboplatin
[23]. Recently, weekly topotecan had been investigated to combine
with the targeted agents such as bevacizumab [24], sorafenib [25],
or lapatinib [26]. Of these, a weekly topotecan and biweekly bev-
acizumab combination demonstrated acceptable toxicity with the
clinical beneﬁt (PR þ SD) rate approaching 60%. This promising
result might be the potential synergistic anti-angiogenic effects of
both agents [27], and their nonoverlapping toxicity proﬁles.
In conclusion, we demonstrated that weekly topotecan IV bolus
was also well tolerated in a heavily pretreated Taiwanese
C.-F. Hu et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 43e47 47population with recurrent EOC and PPC. Our results further sug-
gested that patients who received the lowest dose intensity
(2.75 mg/m2) appeared to gain substantial clinical beneﬁts and a
better toxicity proﬁle. Further investigation of this dosage with
more patients is warranted to conﬁrm this ﬁnding.
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